Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
C Gisselbrecht, D Maraninchi, J L Pico, N Milpied, B Coiffier, M Divine, P Tiberghien, A Bosly, H Tilly, O Boulat, et al.
Interleukin-2 treatment in lymphoma: a phase II multicenter studyBlood. 1994 Apr 15;83(8):2081-5.
C Massumoto, M C Benyunes, G Sale, M Beauchamp, A York, J A Thompson, C D Buckner, A Fefer
Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancyBone Marrow Transplant. 1996 Mar;17(3):351-6.
C Messina, R Zambello, F Rossetti, M V Gazzola, S Varotto, R Destro, G Basso, G Semenzato, L Zanesco
Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patientsBone Marrow Transplant. 1996 May;17(5):729-35.
C Olivier, J Carballido, A H Lao, A Gimeno, C Martín, D Renjifo, L M Ondina, L Manzano, M Alvarez-Mon
[Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)]Actas Urol Esp. 1995 Jan;19(1):16-26.
C Schneekloth, A Körfer, M Hadam, E Lopez Hänninen, T Menzel, A Schomburg, I Dallmann, H Kirchner, H Poliwoda, J Atzpodien
Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivoActa Haematol. 1993;89(1):13-21.
Caligiuri MA, Murray C, Robertson MJ et al.
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.J Clin Invest. 1993 Jan;91(1):123-32. doi: 10.1172/JCI116161. PMID: 7678599; PMCID: PMC330005.
Cañas CA.
The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals.Med Hypotheses. 2020 Dec;145:110345. doi: 10.1016/j.mehy.2020.110345. Epub 2020 Oct 14. PMID: 33080459; PMCID: PMC7556280.
Carsten Krieg, Sven Létourneau, Giuseppe Pantaleo, Onur Boyman
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11.
Cawcutt K.A., Kalil A.C. 
PDF
Saved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?*
Critical Care Medicine. — 2019. — V. 47. — N. 5.
Chikileva I.O., K.S. Titov, V.M. Abramov, V.S. Khlebnikov, I.Z. Shubina, Kiselevsky M.V.
Role of regulatory T cells (Tregs) in Cancer Progression and Interference with Immunotherapy of Cancer.
In Book: Cancer Clusters. Nova Science Publishers, New York, 2011
Chikileva IO, Shubina IZ, Baronzio G, Kiselevsky MV
Is it necessary to deplete the lymphokine activated killers’ populations of CD4+CD25+ lymphocytes. Regulatory Foxp3-positive T cells within lymphokine activated killers.
Biomed Pharmacother. 2010 Jul;64(6):379-85
Chunmiao Zhao, Yanfang Chu, Zhaoyun Liang et al.
Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.Zhao et al. BMC Immunology. — 2019. — P. 20:32.
Clark JW, Smith JW 2nd, Steis RG et al.
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Cancer Res. 1990 Nov 15;50(22):7343-50. PMID: 2224862.
Clark JW, Smith JW, Steis RG et al.
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.Cancer Res. 1990 Nov 15;50(22):7343-50. PMID: 2224862.
Cong-Jun Wang, Chao Wang, Jiang Han et al.
Effect of Combined Treatment With Recombinant interleukin-2 and Allicin on Pancreatic Cancer.Mol Biol Rep. 2013 Dec;40(12):6579-85. doi: 10.1007/s11033-013-2766-1. Epub 2013 Oct 18.
Cortes JE, Kantarjian HM, O’Brien S et al.
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.Cancer. 1999 Apr 1;85(7):1506-13.
Crespo M, Caragol I, Falcó V et al.
Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.Enferm Infecc Microbiol Clin. 2008 Jan;26(1):27-31.
Cидоров И.А., Зыятдинов К.Ш, Добров А.В., Сидорова О.А., Белопухов В.М. PDF
Электронный журнал «Современные проблемы науки и образования». – 2012. – № 3.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.